Information Provided By:
Fly News Breaks for January 22, 2020
SNY, REGN
Jan 22, 2020 | 08:18 EDT
Oppenheimer analyst Hartaj Singh raised his price target for Regeneron (REGN) to $450 from $430 after meeting with management and receiving a "surprisingly positive update." The abating of Eylea competitive dynamics, a strong end to 2019, an intensified focus on Dupixent by the new CEO at partner Sanofi (SNY), a simplification of the Sanofi/Regeneron antibody agreement that could be accretive in 2020, a burgeoning internally generated pipeline that is best-in-class and a renewed focus on cost control give him greater conviction on the name. The analyst has an Outperform rating on Regeneron's shares.
News For REGN;SNY From the Last 2 Days
SNY
Mar 27, 2024 | 06:16 EDT
Wells Fargo analyst Derek Archila raised the firm's price target on Annexon (ANNX) to $12 from $11 and keeps an Overweight rating on the shares. The firm believes the risk/reward remains favorable ahead of ANX005's Phase 3 data in GBS. Additionally, updates for ANX007 at ARVO, Phase 3 GBS data at PNS and read through from Sanofi's (SNY's) riliprubart in CIDP at AAN, all could offer upside for shares, Wells adds.